Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Paolo TarantinoNabihah TayobGuillermo VillacampaChau DangDenise A YardleySteven Jay IsakoffVicente ValeroMeredith FaggenTherese Marie MulveyRon BoseDouglas WecksteinAntonio C WolffKatherine E Reeder-HayesHope S RugoBhuvaneswari RamaswamyDan ZuckermanLowell HartVijayakrishna K GadiMichael ConstantineKit ChengAudrey Merrill GarrettP Kelly MarcomKathy S AlbainPatricia DeFuscoNadine M TungBlair ArdmanRita NandaRachel C JankowitzMothaffar F RimawiVandana G AbramsonPaula R PohlmannCatherine H Van PoznakAndres Forero-TorresMinetta C LiuKathryn J RuddyAdrienne G WaksMichelle DeMeoHarold J BursteinAnn H PartridgePatrizia Dell'OrtoLeila RussoEmma KrauseDaniel J NewhouseBusem Binboğa KurtElizabeth A MittendorfBryan Paul SchneiderAdrienne G WaksEric P WinerIan E KropSara M Tolaneynull nullnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Adjuvant T-DM1 for 1 year leads to outstanding long-term outcomes for patients with stage I HER2-positive breast cancer. A high HER2DX risk score predicted a higher risk of recurrence in ATEMPT.